The National Institutes of Health-funded Trial to Assess Chelation Therapy (TACT) randomized 1708 stable coronary disease patients aged ≥50 years who were ≥6 months post-myocardial infarction (2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010) to 40 infusions of a multicomponent EDTA chelation solution or placebo. Chelation reduced the primary composite end point of mortality, recurrent myocardial infarction, stroke, coronary revascularization, or hospitalization for angina (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P=0.035). Methods and Results-In a randomly selected subset of 911 patients, we prospectively collected a battery of quality-of-life (QOL) instruments at baseline and at 6, 12, and 24 months after randomization. The prespecified primary QOL measures were the Duke Activity Status Index (Table I in the Data Supplement) and the Medical Outcomes Study Short-Form 36 Mental Health Inventory-5. All comparisons were by intention to treat. Baseline clinical and QOL variables were well balanced in the 451 patients randomized to chelation and in the 460 patients randomized to placebo. The Duke Activity Status Index improved in both groups during the first 6 months of therapy, but we found no evidence for a treatment-related difference (mean difference [chelation−placebo] during follow-up, 0.9 [95% confidence interval, −0.7 to 2.6; P=0.27]).
U se of intravenous EDTA to treat atherosclerotic diseases dates back to the mid-1950s. Clinicians using the drug to treat lead toxicity noted a concomitant unexpected improvement in patient-reported angina symptoms. Because the drug's only known mechanism of action was to bind heavy metal cations (eg, calcium, magnesium, and lead) and facilitate their excretion, early users of this therapy speculated that EDTA provided benefit by chelating the calcium in atherosclerotic plaques, thereby facilitating a debulking of symptom-causing plaques. As the understanding of the pathobiology of atherosclerosis advanced, the implausibility of this mechanism, together with the absence of supporting clinical outcome evidence beyond the level of case reports, led mainstream cardiovascular practitioners to reject EDTA chelation therapy. Some practitioners, however, continued to use chelation for atherosclerotic disease based on anecdotal impressions of clinical improvement. A 2007 survey suggested that >110 000 patients in the United States receive this treatment each year. 1 The National Institutes of Health released a request for applications in 2001 and then funded the Trial to Assess Chelation Therapy (TACT) in 2002 to evaluate, in a rigorous randomized clinical trial, the benefits and harms of this therapy in coronary disease patients treated with modern evidence-based therapies. Assessment of patient-reported quality-of-life (QOL) outcomes was a major secondary aim of the TACT research effort, and this article reports the QOL results in the chelation arms of the trial.
Methods

Patient Population and Primary Clinical Results
The TACT is a randomized, double-blind, placebo-controlled, 2×2 factorial trial comparing 40 infusions of a multicomponent EDTA chelation solution with placebo and oral high-dose multivitamin and mineral supplement with placebo in stable post-myocardial infarction (MI) patients. The primary end point was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. Complete inclusion and exclusion criteria have been previously published. 2 All patients provided informed consent, and study protocol approval was obtained from each site's institutional review board or ethics committee.
A total of 1708 patients were enrolled (839 to chelation and 869 to placebo) at 134 clinical sites in the United States and Canada between September 10, 2003 , and October 4, 2010. 3 Median follow-up was 55 months. The median age was 65 years, 18% were women, and 94% were white. At baseline, the use of evidence-based medicines was high and did not differ between the EDTA and placebo groups: aspirin, warfarin, or clopidogrel, 91%; β-blockers, 72%; statins, 73%; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 63%. Follow-up medication use remained at high levels through the last follow-up and did not differ by treatment group: aspirin, warfarin, or clopidogrel, 87%; β-blocker, 72%; statins, 68%; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 61%. Coronary revascularization during follow-up occurred in 15% of the EDTA chelation patients and 18% of the placebo patients. 3 As previously reported, the primary intention-to-treat comparison showed that the primary end point occurred in 26% of the patients assigned to chelation and in 30% assigned to placebo (hazard ratio, 0.82; 95% confidence interval [CI], 0.69-0.99; P=0.035). 3 The magnitude of treatment effect of chelation on the nonfatal components of the primary end point was consistent with its overall effect (no single component dominant). No evidence for a mortality effect was seen, but power for this end point was low. Two prespecified subgroups, patients with diabetes mellitus and patients with a prior anterior MI, received particular benefit from the chelation strategy. 4
Patient Selection and Health-Related QOL Data Collection
As a result of budgetary considerations, a decision was made at the outset of TACT to enroll ≈50% of the total study cohort into the QOL substudy. Patients were selected for QOL data collection by simple random selection at the time of treatment assignment. Health-related QOL data were collected using interviews at baseline and at 6, 12, and 24 months after randomization. Site coordinators were specially trained to administer the QOL baseline interviews. Follow-up interviews were conducted via telephone by trained interviewers from the Duke Clinical Research Institute's Outcomes Research Group. Proxy forms were collected for patients who were unable to participate in the full interview because of illness or incapacity (≈3%-5% of surviving patients at each follow-up assessment; Figure 1 class were collected on the clinical case report form at baseline and each follow-up interval.
QOL Measures
A battery of validated measures was collected to provide a comprehensive but efficient assessment of QOL in TACT. Two principal QOL measures were prespecified during the design phase of the study as being most likely to show a treatment effect: the Duke Activity Status Index (DASI) and the Short Form-36 (SF-36) Mental Health Inventory-5 (MHI-5). The DASI is a 12-item instrument used to assess cardiac-related functional status. 5 Scores range from 0 (worst) to 58.2 (best) and reflect the ability of patients to do physical activities without difficulty or assistance in 12 domains (see Appendix in the Data Supplement). For an individual patient, a clinically significant change is considered to be ≥4 points. 6 Item selection and weighting in DASI were performed using a cardiopulmonary exercise testing reference standard. 5 The MHI-5 assesses psychological well-being, including depression and anxiety. 7 It is scored from 0 (worst) to 100 (best). A clinically significant change for an individual patient is approximated by a one-fourth SD difference, ≈5 points. We also collected 3 scales from the Seattle Angina Questionnaire (SAQ) to assess the impact of angina symptoms on QOL outcomes. 8 The SAQ anginal frequency scale assesses the frequency of angina symptoms in the previous 4 weeks. Higher scores reflect fewer angina symptoms. The SAQ anginal stability scale measures changes in angina frequency, with a score of 50 representing no change and higher scores indicating less frequent angina compared with the previous month. The SAQ QOL scale measures the effect of angina symptoms on patients' perceptions of their QOL, with higher scores being more favorable. For SAQ scales, ≥5 points represent a benchmark for a clinically significant change for an individual patient. 8 To provide an overview of functioning and well-being from a generic perspective, we also collected individual scales from the Medical Outcomes Study SF-36: general health, physical function, role functioning-physical, role functioning-emotional, bodily pain, social function, and vitality (energy/fatigue). 7 These instruments asked patients to recall health status during the past 4 weeks. Higher scores reflect more favorable outcomes. These SF-36 scales can also be used to score 2 additional summary scales: the SF-36 Physical Component and Mental Component. 9 These scores are standardized to a population norm-based average value obtained from the 1998 US general population, with a mean of 50 and an SD of 10. A clinically significant change for a patient using this scoring system has not been established but can be approximated by a one-fourth SD or ≥2.5 points.
We collected the 5-dimensional generic health status index EQ-5D to measure patient utilities (health states weighted by the population preferences for that state), which indicate the relative desirability of each patient's health state on a scale from 0 (dead) to 1 (best possible health). 10
Statistical Analyses
Primary Analyses
All primary comparisons were performed according to the principle of intention to treat. Descriptive statistics included percentages for discrete variables and medians with 25th to 75th percentiles plus means with SDs for continuous variables. The χ 2 test was used for discrete variable comparisons. Treatment comparisons of continuous variables were performed using a regression model to account for repeated measures within a patient, with treatment group, time point, and the respective QOL measure from the baseline questionnaire as predictor variables. Using PROC MIXED in SAS version 9.2, the 6-, 12-, and 24-month measurements within a patient were fitted using an unstructured covariance matrix. 11 At each time point, estimated treatment differences, 95% confidence intervals, and P values were obtained using estimate statements. These models assumed that missing data were missing at random. Time and treatment groups were coded using a cell mean model, with 8 binary variables representing the 4 QOL assessment points and 2 treatment groups.
All reported P values were 2-sided, and the conventional Neyman-Pearson decision rule for rejecting the null hypothesis was used (P<0.05). No adjustment was made in significance levels for multiple comparisons.
As an aid to interpretation, we considered evidence supporting a QOL effect to be present if we saw either a consistent treatment difference over multiple consecutive follow-up contacts or a concordant treatment difference in multiple-related QOL measures.
Subgroups
We compared QOL outcomes according to the prespecified subgroups set forth for the overall TACT analysis: sex, minorities, elderly (>70 years), anterior MI, diabetes mellitus, metabolic syndrome, statin therapy, interaction with high-dose vitamin/mineral arm, and type of enrolling site (chelation practice or not). 3 Two additional subgroups were examined that were not prespecified: angina at baseline (Canadian Cardiovascular Society class >0) and heart failure at baseline (New York Heart Association class >0).
Results
Baseline Characteristics and QOL Data Collection Rates
We randomly selected 911 (53.3%) of the 1708 patients enrolled in the TACT trial for the QOL substudy. In this QOL cohort, 451 patients were randomized to EDTA and 460 to placebo. The baseline characteristics of the study population were representative of the parent study population and were well balanced between the 2 treatment arms ( Table 1) . Overall, the median age was 65 years, 19% were women, and 93% were non-Hispanic whites.
From a total of 3403 expected follow-up patient QOL contacts out to 24 months, 3288 (96.6%) QOL questionnaires were collected. Expected contacts exclude deaths and withdrawals. The rate of missing QOL assessments did not differ by treatment group at baseline or any follow-up interval (Figure 1 ).
QOL Outcomes
Prespecified Principal Patient-Reported QOL End Points
Both treatment groups showed an improvement in patientreported cardiac-related physical functioning, as assessed using the DASI, in follow-up compared with baseline assessments (Table 2; Figure 2 ). At baseline, the chelation group had a mean DASI score of 24.6, which improved to 29.1 at 6 months and 29.4 at 12 months but then fell to 27.1 at 24 months. The placebo group had a mean DASI score of 23.5 at baseline, 27.0 at 6 months, 26.3 at 12 months, and 25.1 at 24 months. After adjustment, between-group differences averaged 0.9 DASI points during the 24 months of QOL follow-up (95% CI, −0.7 to 2.6) and were not statistically different at any time point.
Both treatment groups had baseline MHI-5 scores that were at the population-level benchmark (score of 50), indicating that there was no initial deficit in this QOL domain. Comparison of adjusted follow-up values showed that there were no clinically or statistically significant differences at any time point (mean overall adjusted difference between treatment groups, 1.0 [95% CI, −0.1 to 2.0]; Table 2; Figure 3 ).
Additional Patient-Reported QOL Measures
The SAQ anginal frequency scale exhibited a ceiling effect at baseline (median value was 100, which is the highest value of the scale, indicating no angina), corresponding to a baseline prevalence of Canadian Cardiovascular Society class >0 of 21%. Median observed values remained at 100 for both treatment groups during follow-up, and no difference in the distribution of adjusted values was evident by treatment ( Table 3 ). The SAQ QOL scale, reflecting patient satisfaction with aspects of their life affected by angina, showed improvement in both treatment groups from baseline to initial follow-up, with little change thereafter and with no differential pattern according to treatment group (Table 3) .
Other secondary QOL measures, including the SF-36 generic health status scales and summary measures, did not show any clinically or statistically significant treatment differences between groups at any follow-up interval (Tables II  and III Association class nor the Canadian Cardiovascular Society angina class showed any evidence of a treatment-related difference ( Table IV in 
Prespecified Subgroup Analysis
None of the prespecified subgroups showed a treatment effect on QOL (data not shown). In particular, there were no treatment-specific QOL differences among patients with diabetes mellitus or anterior MI. Of the 2 post hoc subgroups we examined, no treatment effect was seen in the patients with heart failure symptoms at baseline. The 21% of TACT patients with angina symptoms at baseline (Canadian Cardiovascular Society class >0) had a 2.44 difference in DASI points at 6 months (P=0.20), a 4.99-point difference at 1 year (P=0.019), and a 1.21-point difference at 24 months (P=0.57), with an overall average difference of 2.86 DASI points (P=0.097) favoring EDTA chelation. No differences were seen in the SF-36 MHI-5 or the secondary QOL measures.
Discussion
The National Institutes of Health funded TACT in 2002 to assess whether EDTA chelation had therapeutically useful biological activity in coronary artery disease. TACT was also charged with defining the safety of this therapy. The primary clinical results of TACT have now been reported and show that during a 55-month median follow-up period, EDTA chelation did produce a clinically important and statistically significant reduction in the composite primary end point of the trial. 3 Of particular note, the pattern of benefit was not confined to a single component of the composite end point but was consistent across all the nonfatal components. No treatment effect was seen for mortality, but the study lacked power to make this evaluation.
A major prespecified secondary end point of TACT was health-related QOL. Because chelation therapy was used in TACT in a stable post-MI population in anticipation of future events more than as a treatment for ongoing cardiac symptoms, its likely effects on QOL during the duration of the study were uncertain at the time the substudy was designed. In addition, we had no prior data involving the use of chelation therapy for coronary artery disease that would have allowed us to anticipate the specific QOL benefits of the chelation strategy being tested in TACT. Therefore, we made the general assumption that most likely beneficial QOL effects of chelation in coronary disease patients, if there were any to be found, would manifest as less angina and consequent improved functional status. We assembled a comprehensive but efficient QOL battery that was expected to provide reasonable ability to detect both positive and negative effects of chelation therapy. Recognizing that comparison of multiple QOL scales at multiple different time points might lead to differences because of chance rather than treatment and without any relevant prior chelation therapy research to guide us, we prespecified 2 QOL measures, DASI and MHI-5, as our primary measures of interest and assigned all the remaining measures to a secondary status.
Our primary finding in the present study is that chelation therapy did not have a detectable effect on health-related QOL in TACT. Averaged during 24 months of follow-up, the EDTA chelation arm differed from the placebo arm by 0.9 DASI units (95% CI, −0.7 to 2.6) and 1 unit on the MHI-5 0 to 100 scale (95% CI, −0.1 to 2.0). Based on power projections made during the planning phase of the study, 900 patients should have provided us with >90% power to detect the minimal clinically important difference in DASI (4 DASI units or 1/4 of an SD). Because the mechanism of the therapeutic action of EDTA chelation demonstrated in the overall TACT results remains unclear, the absence of a QOL effect is consistent with several different explanations. One possibility is that EDTA chelation alters aspects of coronary artery disease progression that do not have symptomatic correlates. The previously reported clinical results showed a treatment effect on coronary revascularization and hospitalization for angina. Although both of those end points would be expected to have a symptomatic element, it is possible that the duration of symptoms was truncated by application of effective therapies, and no long-term decrements in QOL were produced. Another possible explanation for our negative findings is that TACT selected a population in which there was little opportunity for a QOL benefit to be produced because of the low level of cardiac symptoms present at the time of enrollment. For example, if only some patients with coronary artery disease have the potential to experience a QOL benefit from EDTA chelation, such as those with baseline anginal symptoms (comprising 21% of our sample), our power would have been much lower than the estimate calculated above under the assumption that all patients could experience benefit. This possibility suggests that the effectiveness of this form of therapy to improve symptoms and functioning in patients with chronic cardiac symptoms will require additional study. Little modern clinical research on EDTA chelation therapy has been published. Several small trials of a 20-week regimen of chelation have been performed in intermittent claudication patients. 12, 13 These did not show any evidence of a therapeutic effect. No prior trials have examined the effects of this therapy on either clinical events or QOL in a population similar to TACT.
Examination of subgroup effects in a clinical trial is routine but must be approached with caution because of both the reduced precision of estimated treatment effect sizes and the possibility of chance variations in the data being misinterpreted as a treatment-related effect. None of the prespecified subgroups we examined showed any treatment signal on QOL outcomes. Of the 2 post hoc subgroups we evaluated, only the patients with angina at baseline showed a suggestion of a treatment effect evident on cardiac-related functional status (DASI) at 6 months, peaking at 1 year and then greatly attenuated at 2 years. These data, therefore, are not clear enough to be confident that a chelation-related treatment effect is responsible for the observed differences.
Rates of use of evidence-based medicine were generally high in this trial, and no treatment-related differences were seen during follow-up. Coronary revascularization was reduced by 3 per 100 by EDTA chelation at the end of followup, 3 but no difference was seen by the 2-year follow-up in our QOL sample. Thus, the likelihood that differential use of medical therapies or revascularization affected our results so as to have masked a treatment-related difference seems small.
Several caveats should be considered in the interpretation of our results. As mentioned earlier, the selection of a trial population that was largely asymptomatic at baseline may have reduced our chances for observing an effect of treatment on QOL. Additional study in patients with chronic angina will be required to assess the possibility that EDTA does have an effect on ischemic symptoms. Because of a limitation in funding for this part of the TACT program, we were not able to obtain follow-up QOL assessments beyond 2 years. Although the anecdotal reports of symptomatic benefit of chelation suggest an effect that should be detectable within the first 2 years, the pattern of prognostic benefits evident in the overall TACT trial raises the possibility that the effects of chelation are biologically persistent long after the infusion phase of therapy has concluded.
Another potential limitation of our study relates to the amount of missing QOL data we had (Figure 1 ). Most analytic approaches to QOL data make the useful, but unprovable, assumption that missing data are missing at random. However, when data are missing because of either death or illness severity, the missing at random assumption is unlikely to be true. In the present study, treatment had no effect on mortality, and relatively equal numbers of patients were missing QOL data but alive at each follow-up point. These 2 factors make it unlikely that the missing data caused a clinically important bias in measured QOL effects, resulting in the masking of a true QOL benefit of chelation.
In conclusion, our study shows that in a population of stable, largely asymptomatic coronary artery disease patients with prior MI, use of EDTA chelation therapy did not produce a measurable change in health-related QOL during 2 years of follow-up. 
